Kyverna Therapeutics, Inc.

KYTX Nasdaq SEC CIK 1994702
Follow Kyverna Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$41.9M −14% vs same quarter last year
EPS, diluted −$0.68 +20% vs same quarter last year
Operating cash flow −$35.4M +18.4% vs same quarter last year
Operating income −$42.9M −10.8% vs same quarter last year
Net income by quarter
−$37.5M
−$44.6M
−$42.1M
−$36.8M
−$37.8M
−$39.7M
−$38.3M
−$41.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
−$200M−$150M−$100M−$50M$0FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$161.3M
FY24−$127.5M
FY23−$60.4M
FY22-
Free cash flowOperating cash flow minus capital expenditure
−$200M−$150M−$100M−$50M$0FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$153.7M
FY24−$116.5M
FY23−$53M
FY22-